person · Reporting owner

Schlesinger Sarah J.

Disclosed activity across 4 companies

Tapewire entity: 49455
SEC CIK: 0001579873

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Armata Pharmaceuticals, Inc.ARMP · Entity 6329	Director	March 09, 2026	March 12, 2026
Innoviva, Inc.INVA · Entity 4679	Director	May 04, 2026	May 06, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Armata Pharmaceuticals, Inc.

Report date March 09, 2026 · Filed March 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.61 · Expires 2036-03-09	Direct	25,640	Reported balance After 2026-03-09 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-03-09 · Grant · Acquired 25,640 · Balance 25,640 F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date.

Innoviva, Inc.

Report date May 04, 2026 · Filed May 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	140,492	Reported balance After 2026-05-04 transaction · row 1 1 source row Row 1 · 2026-05-04 · Grant · Acquired 9,786 · Balance 140,492 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.
Non-statutory Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $22.99 · Expires 2036-05-03	Direct	10,000	Reported balance After 2026-05-04 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ARIAD PHARMACEUTICALS INC

Report date February 13, 2017 · Filed February 16, 2017

Section 16 reporting ended · disclosed 2017-02-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSpouse	Reported balance After 2017-02-13 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2017-02-13 · Gift · Disposed 15,600 · Balance 0
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-02-16 transaction · row 2 1 source row Row 2 · 2017-02-16 · Disposition to issuer · Disposed 55,508 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.98	Direct	Reported balance After 2017-02-16 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-02-16 · Disposition to issuer · Disposed 40,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.39	Direct	Reported balance After 2017-02-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.45	Direct	Reported balance After 2017-02-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.91	Direct	Reported balance After 2017-02-16 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.82	Direct	Reported balance After 2017-02-16 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2017-02-16 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash.

F2: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes.

F3: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0.

MEDICINES CO /DE

Report date January 06, 2020 · Filed January 06, 2020

Section 16 reporting ended · disclosed 2020-01-06. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-06 transaction · row 1 1 source row Row 1 · 2020-01-06 · Disposition to issuer · Disposed 7,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.83	Direct	Reported balance After 2020-01-06 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-06 · Disposition to issuer · Disposed 26,383 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $33.86	Direct	Reported balance After 2020-01-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-06 · Disposition to issuer · Disposed 9,141 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $34.81	Direct	Reported balance After 2020-01-06 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-06 · Disposition to issuer · Disposed 8,410 · Balance 0 F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price").

F2: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share.

F3: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 04, 2026 Filed May 6, 2026 20:15 UTC	Innoviva, Inc. INVA · Entity 4679	GrantNon-statutory Stock Option · Derivative	10,000	$0.00 Strike: $22.99	$0.00	Disclosure SEC source: 0001193125-26-209006 · ownership.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-05-03 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document
May 04, 2026 Filed May 6, 2026 20:15 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	9,786	$0.00	$0.00	Disclosure SEC source: 0001193125-26-209006 · ownership.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,492 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and non-statutory stock options ("Options") upon the conclusion of the Issuer's 2026 annual meeting of stockholders. 100% of the RSUs and Options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date, with accelerated vesting upon the Reporting Person's death, disability, or in the event of a "change in control" (as defined in the Issuer's 2026 Equity Incentive Plan), provided that the Reporting Person has not experienced a termination prior to such "change in control," death or disability. Read SEC document
March 09, 2026 Filed Mar 12, 2026 01:14 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Options (Right to Buy) · Derivative	25,640	$0.00 Strike: $11.61	$0.00	Disclosure SEC source: 0001104659-26-026581 · tm268588-2_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,640 Underlying: Common Stock · 25,640 shares Expires 2036-03-09 F1 · derivative.exercise_date: The Stock Options will vest in full on March 9, 2027, subject to continuous service through the vesting date. Read SEC document
May 19, 2025 Filed May 22, 2025 01:34 UTC	Innoviva, Inc. INVA · Entity 4679	GrantNon-statutory Stock Option · Derivative	10,000	$0.00 Strike: $18.63	$0.00	Disclosure SEC source: 0001104659-25-051747 · tm2515701-4_4seq1.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-18 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
May 19, 2025 Filed May 22, 2025 01:34 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	12,077	$0.00	$0.00	Disclosure SEC source: 0001104659-25-051747 · tm2515701-4_4seq1.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,706 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2025 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
February 05, 2025 Filed Feb 7, 2025 21:21 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Options (Right to Buy) · Derivative	54,343	$0.00 Strike: $2.04	$0.00	Disclosure SEC source: 0001104659-25-010567 · tm255864-8_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,343 Underlying: Common Stock · 54,343 shares Expires 2035-02-05 F1 · derivative.exercise_date: The Options shall vest (i) 50% on February 5, 2026 and (ii) 50% on February 5, 2027, in each case subject to continuous service through such vesting date. Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:58 UTC	Innoviva, Inc. INVA · Entity 4679	GrantNon-statutory Stock Option · Derivative	10,000	$0.00 Strike: $16.16	$0.00	Disclosure SEC source: 0001104659-24-073449 · tm2417570-4_4seq1.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:58 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	13,923	$0.00	$0.00	Disclosure SEC source: 0001104659-24-073449 · tm2417570-4_4seq1.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,629 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2024 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
March 14, 2024 Filed Mar 19, 2024 00:02 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Options (Right to Buy) · Derivative	54,343	$0.00 Strike: $3.38	$0.00	Disclosure SEC source: 0001104659-24-035727 · tm249071-6_4seq1.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,009 Underlying: Common Stock · 54,343 shares Expires 2034-03-14 F2 · derivative.exercise_date: The Options shall vest (i) 50% on March 14, 2025 and (ii) 50% on March 14, 2026, in each case subject to continuous service through such vesting date. Read SEC document
March 14, 2024 Filed Mar 19, 2024 00:02 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Options (Right to Buy) · Derivative	39,666	$0.00 Strike: $3.38	$0.00	Disclosure SEC source: 0001104659-24-035727 · tm249071-6_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,666 Underlying: Common Stock · 39,666 shares Expires 2034-03-14 F1 · derivative.exercise_date: The Options shall vest upon the Company's 2024 annual shareholders meeting subject to the Non-Employee Director's continuous service through immediately prior to the convening of such meeting, with the date of grant being March 14, 2024. Read SEC document
December 21, 2023 Filed Dec 27, 2023 02:55 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Options (Right to Buy) · Derivative	10,461	$0.00 Strike: $2.39	$0.00	Disclosure SEC source: 0001104659-23-129371 · tm2333426-4_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,461 Underlying: Common Stock · 10,461 shares Expires 2033-12-21 F1 · derivative.exercise_date: The stock option vests immediately prior to the Company's 2024 annual shareholders meeting. Read SEC document
May 22, 2023 Filed May 24, 2023 21:54 UTC	Innoviva, Inc. INVA · Entity 4679	GrantNon-statutory Stock Option · Derivative	10,000	$0.00 Strike: $13.64	$0.00	Disclosure SEC source: 0001104659-23-064213 · tm2316873-4_4seq1.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2033-05-21 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
May 22, 2023 Filed May 24, 2023 21:54 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	16,495	$0.00	$0.00	Disclosure SEC source: 0001104659-23-064213 · tm2316873-4_4seq1.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,706 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2023 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
April 25, 2022 Filed Apr 27, 2022 22:48 UTC	Innoviva, Inc. INVA · Entity 4679	GrantNon-statutory Stock Option · Derivative	10,000	$0.00 Strike: $17.79	$0.00	Disclosure SEC source: 0001567619-22-009042 · doc1.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2032-04-24 F1 · derivative.exercise_date: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
April 25, 2022 Filed Apr 27, 2022 22:48 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	12,647	$0.00	$0.00	Disclosure SEC source: 0001567619-22-009042 · doc1.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,211 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") and options upon the conclusion of the Issuer's 2022 annual meeting of stockholders. 100% of the RSUs and options will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
April 13, 2022 Filed Apr 15, 2022 19:54 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Options (Right to Buy) · Derivative	33,000	$0.00 Strike: $5.11	$0.00	Disclosure SEC source: 0001104659-22-046453 · tm2212851-7_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,000 Underlying: Common Stock · 33,000 shares Expires 2032-04-13 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document
June 07, 2021 Filed Jun 9, 2021 20:26 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Option (Right to Buy) · Derivative	28,000	$0.00 Strike: $4.29	$0.00	Disclosure SEC source: 0001104659-21-078789 · tm2119245-5_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2031-06-07 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document
May 14, 2021 Filed May 21, 2021 00:14 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	17,482	$0.00	$0.00	Disclosure SEC source: 0001567619-21-010827 · doc1.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,564 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs") upon the conclusion of the Issuer's 2021 annual meeting of stockholders. 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
December 08, 2020 Filed Dec 9, 2020 21:07 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Option (Right to Buy) · Derivative	23,000	$0.00 Strike: $3.15	$0.00	Disclosure SEC source: 0001104659-20-133637 · tm2038059-5_4seq1.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires 2030-12-08 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each of the first and second annual anniversaries of the date of grant. Read SEC document
April 24, 2020 Filed Apr 28, 2020 20:09 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	16,917	$0.00	$0.00	Disclosure SEC source: 0001567619-20-008542 · doc1.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,082 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
February 12, 2020 Filed Feb 14, 2020 23:04 UTC	Armata Pharmaceuticals, Inc. ARMP · Entity 6329	GrantStock Option (Right to Buy) · Derivative	27,383	$0.00 Strike: $4.17	$0.00	Disclosure SEC source: 0001104659-20-022097 · tm208184-3_form4.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,383 Underlying: Common Stock · 27,383 shares Expires 2030-02-12 F1 · derivative.exercise_date: The stock option vests as to fifty percent (50%) of the underlying shares of common stock on each annual anniversary of the date of grant. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:30 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	8,410	$0.00 Strike: $34.81	$0.00	Disclosure SEC source: 0000950142-20-000048 · es2000133_4-schlesinger.xml · derivative · entry 4 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,410 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:30 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	9,141	$0.00 Strike: $33.86	$0.00	Disclosure SEC source: 0000950142-20-000048 · es2000133_4-schlesinger.xml · derivative · entry 3 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,141 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:30 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerStock Option · Derivative	26,383	$0.00 Strike: $29.83	$0.00	Disclosure SEC source: 0000950142-20-000048 · es2000133_4-schlesinger.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,383 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option (each an "Option") that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser, whether vested or unvested, became fully vested and was canceled as of immediately prior to, and contingent upon, the effective time of the Merger, in exchange for the right to receive an amount in cash equal to the product of (x) the excess (if any) of the Offer Price over the per share exercise price payable in respect of each Share issuable under such Option, multiplied by (y) the number of Shares issuable under such Option. Read SEC document
January 06, 2020 Filed Jan 6, 2020 13:30 UTC	MEDICINES CO /DE MDCO · Entity 152552	Disposition to issuerCommon Stock	7,429	Not disclosed	Not disclosed	Disclosure SEC source: 0000950142-20-000048 · es2000133_4-schlesinger.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of November 23, 2019 (the "Merger Agreement"), by and among the Company, Novartis AG ("Parent") and Medusa Merger Corporation ("Purchaser"), on January 6, 2020, Purchaser was merged with and into the Company (the "Merger"), with the Company surviving the Merger as an indirect wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each a "Share") was converted into the right to receive $85.00 per Share, net to the seller in cash (the "Offer Price"). F2 · price: The number of Shares reported includes 3,663 unvested restricted Shares (each a "Restricted Share"). Each Restricted Share that was outstanding immediately prior to the consummation of the tender offer by Parent and Purchaser automatically became fully vested as of immediately prior to, and contingent upon, the effective time of the Merger and was treated in the same manner as an outstanding Share. Read SEC document
May 30, 2019 Filed Jun 3, 2019 17:11 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	8,410	$0.00 Strike: $34.81	$0.00	Disclosure SEC source: 0001179110-19-007026 · edgar.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,410 Underlying: Common Stock · 8,410 shares Expires 2029-05-30 F2 · derivative.exercise_date: The option vests in one installment on May 30, 2020 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 30, 2019 Filed Jun 3, 2019 17:11 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,663	$0.00	$0.00	Disclosure SEC source: 0001179110-19-007026 · edgar.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,429 F1 · shares: The restricted stock award vests on May 30, 2020 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
April 24, 2019 Filed May 25, 2019 01:58 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	16,399	$0.00	$0.00	Disclosure SEC source: 0001104659-19-031861 · a4.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,165 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:54 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantStock Option (right-to-buy) · Derivative	9,141	$0.00 Strike: $33.86	$0.00	Disclosure SEC source: 0001179110-18-007957 · edgar.xml · derivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,141 Underlying: Common Stock · 9,141 shares Expires 2028-05-31 F2 · derivative.exercise_date: The option vests in one installment on May 31, 2019 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
May 31, 2018 Filed Jun 4, 2018 16:54 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCommon Stock	3,766	$0.00	$0.00	Disclosure SEC source: 0001179110-18-007957 · edgar.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,766 F1 · shares: The restricted stock award vests on May 31, 2019 and was made as part of and pursuant to the Issuer's director compensation program. Read SEC document
April 24, 2018 Filed Apr 26, 2018 20:10 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	14,249	$0.00	$0.00	Disclosure SEC source: 0001179110-18-005885 · edgar.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,766 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual stockholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. Read SEC document
February 22, 2018 Filed Feb 26, 2018 21:46 UTC	MEDICINES CO /DE MDCO · Entity 152552	GrantCall Option (right-to-buy) · Derivative	26,383	$0.00 Strike: $29.83	$0.00	Disclosure SEC source: 0001179110-18-002926 · edgar.xml · derivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,383 Underlying: Common Stock · 26,383 shares Expires 2028-02-22 F1 · derivative.exercise_date: This option vests in one installment on February 22, 2021 and is made part of and pursuant to Issuer's director compensation package. Read SEC document
February 12, 2018 Filed Feb 14, 2018 22:39 UTC	Innoviva, Inc. INVA · Entity 4679	GrantCommon Stock	10,517	$0.00	$0.00	Disclosure SEC source: 0001179110-18-002082 · edgar.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,517 Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $23.82	$0.00	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · derivative · entry 7 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $4.91	$0.00	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · derivative · entry 6 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $6.45	$0.00	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · derivative · entry 5 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $7.39	$0.00	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · derivative · entry 4 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerStock Option (Right to Buy) · Derivative	40,000	$0.00 Strike: $20.98	$0.00	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · derivative · entry 3 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the tender offer by Takeda and Purchaser to acquire all the outstanding Shares for $24.00 in cash (the "Offer"), whether vested or unvested, automatically became fully vested and was canceled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $24.00 over (y) the exercise price payable in respect of each Share issuable under such Option; provided, however, that the Option Consideration for each Option with an exercise price equal to or greater than $24.00 shall be $0. Read SEC document
February 16, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	Disposition to issuerCommon Stock	55,508	Not disclosed	Not disclosed	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · nonDerivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 8, 2017 (the "Merger Agreement"), between the Company, Takeda Pharmaceutical Company Limited ("Takeda") and Kiku Merger Co., Inc. ("Purchaser"), on February 16, 2017, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $24.00 in cash. F2 · price: The number of Shares reported includes 5,508 unvested restricted Shares subject to a lapsing right of repurchase by the Company (each, a "Restricted Share") and 12,500 Shares underlying unvested restricted stock units (each, an "RSU"). By virtue of the Merger and without any required action on the part of the holder thereof, all vesting conditions and restrictions applicable to each Restricted Share lapsed and each Restricted Share was converted automatically into the right to receive $24.00 in cash. In addition, pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the Merger automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Merger into a vested right to receive a lump-sum cash payment in an amount equal to $24.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
February 13, 2017 Filed Feb 16, 2017 14:18 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GiftCommon Stock	15,600	$0.00	$0.00	Disclosure SEC source: 0000884731-17-000060 · wf-form4_148727268924679.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Spouse Disclosed balance after: 0 Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:56 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantEmployee Stock Option (Right to Buy) · Derivative	25,000	$23.82 Strike: $23.82	$595,500.00	Disclosure SEC source: 0000884731-17-000013 · wf-form4_148598615810983.xml · derivative · entry 4 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-01-31 F3 · derivative.exercise_date: The stock options granted under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy vest as to approximately one-fourth of the shares underlying the options on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:56 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantCommon Stock	12,500	$0.00	$0.00	Disclosure SEC source: 0000884731-17-000013 · wf-form4_148598615810983.xml · nonDerivative · entry 2 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,508 F2 · shares: Represents restricted stock units ("RSUs") granted under our 2014 Long-Term Incentive Plan, as amended, and our director compensation policy. The RSUs vest as to approximately one-fourth of the shares underlying the RSUs on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document
January 31, 2017 Filed Feb 1, 2017 16:56 UTC	ARIAD PHARMACEUTICALS INC ARIA · Entity 134569	GrantCommon Stock	5,508	$0.00	$0.00	Disclosure SEC source: 0000884731-17-000013 · wf-form4_148598615810983.xml · nonDerivative · entry 1 Schlesinger Sarah J. · CIK 0001579873 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,008 F1 · shares: Represents shares of restricted stock granted in lieu of the annual cash retainer under our 2014 Long-Term Incentive Plan, as amended, and in accordance with our director compensation policy. The shares are subject to a lapsing right of repurchase by the Company that lapses as to approximately one-fourth of the shares on the last business day of each calendar quarter in 2017, subject to the terms of the award. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.